Founded in Saint Paul, United States, Syntiron focuses on combating bacterial infections through innovative antigen discovery and purification technology. The company's core mission is to develop vaccines that target bacterial iron transport proteins, which are essential for bacterial survival and pathogenicity. Syntiron aims to address critical health issues such as antimicrobial resistance and urinary tract infections (UTIs), providing lasting protection without the risk of resistance associated with antibiotics.

Syntiron has garnered attention for its cutting-edge research in human vaccine development. The company’s notable affiliations include partnerships with leading research institutions and biotech investors who support its mission to revolutionize vaccine technology. Key achievements include significant advancements in vaccine candidates targeting UTIs and other bacterial infections. Syntiron's impact lies in its potential to reduce global reliance on antibiotics, thereby mitigating the spread of resistant bacteria and enhancing public health outcomes.